DEA Rules on Doctor's Fate in Routine Order
Published Date: 12/22/2025
Notice
Summary
Dr. David Halvorson from Alabama lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of October 31, 2025. This means he can’t prescribe or manage controlled drugs anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Halvorson
The DEA revoked David Halvorson, M.D.'s Certificate of Registration No. BH3453278 and denied any pending applications to renew, modify, or obtain additional registration in Alabama. The Order is effective January 21, 2026; the record also shows his Alabama medical license was revoked on or about June 6, 2025 and his DEA registration expired on October 31, 2025.
DEA Policy: State Authority Required
Under 21 U.S.C. 824(a)(3) and long-standing DEA precedent cited in this Order, the DEA will revoke a practitioner's federal controlled-substances registration if the practitioner no longer has state authority to dispense controlled substances (for example, after a state license suspension or revocation). The Order reiterates that possession of state authority to dispense controlled substances is a fundamental condition for obtaining and maintaining a DEA practitioner registration.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13825 — Designation of Phenethyl Halides as List I Chemicals
The DEA wants to add phenethyl halides to a special list of chemicals that are closely watched because they can be used to make illegal fentanyl. This means anyone handling these chemicals will have to follow new rules starting soon, no matter how much they have. If you work with these chemicals, get ready to comply and share your thoughts by August 10, 2026!
2026-13821 — Schedules of Controlled Substances: Placement of Tianeptine in Schedule I
The DEA wants to put tianeptine, a drug with potential risks, into Schedule I, meaning it’ll be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or uses tianeptine, bringing strict rules and penalties. You’ve got until August 7, 2026, to share your thoughts before the new rules could kick in.
2026-13705 — Importer of Controlled Substances Application: Benuvia Operations, LLC.
Benuvia Operations, LLC wants to become an official importer of certain controlled substances like marijuana extract and psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 6, 2026. This move could shake up who gets to bring these substances into the U.S., so keep an eye on the deadline if you’re interested!
2026-13581 — Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.
Previous / Next Documents
Previous: 2025-23544 — Notice of Inventory Completion: Florida Department of State, Tallahassee, FL
The Florida Department of State has finished checking some Native American human remains and found they belong to the Pueblo of Jemez tribe. Starting January 21, 2026, these remains can be returned to the tribe. This is part of a respectful effort to give back important cultural items and remains to Native communities.
Next: 2025-23546 — Submission for Office of Management and Budget Review; Proposed Information Collection Activity; Office of Community Services Community Economic Development Performance Progress Report
The Office of Community Services is updating how community economic development grant recipients report their progress. New awardees will now submit shorter reports every quarter, while others stick to twice a year. This change helps keep projects on track and improves how the government supports and tracks job creation and spending, with comments due by January 21, 2026.